Dr Reddy's Labs unveils Doxycycline Capsules, 40 mg in US to treat inflammatory lesions of rosacea

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-05-04 05:44 GMT   |   Update On 2024-05-04 05:44 GMT

Hyderabad: Dr Reddy's Laboratories Ltd. has announced its launch of Doxycycline Capsules, 40 mg in the U.S. market, a therapeutic generic equivalent of ORACEA (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA).Doxycycline is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in...

Login or Register to read the full article

Hyderabad: Dr Reddy's Laboratories Ltd. has announced its launch of Doxycycline Capsules, 40 mg in the U.S. market, a therapeutic generic equivalent of ORACEA (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA).

Doxycycline is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Inflammatory lesions, including papules and pustules, are common symptoms of rosacea. These lesions manifest as raised, red bumps (papules) and pus-filled bumps (pustules) on the skin, typically on the face. They are often accompanied by redness, swelling, and sensitivity in the affected areas.

Dr. Reddy’s Doxycycline Capsules, 40 mg, are supplied in bottle counts of 30. Each capsule contains: 26 mg immediate-release pellets and 14 mg delayed-release pellets equivalent to 40 mg of anhydrous doxycycline, USP.

ORACEA is a trademark of Galderma Holdings, S.A.

Read also: Nestle India, Dr Reddy's to form JV to bring nutraceutical brands to consumers in India, other agreed territories

Established in 1984, Dr Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. Dr Reddys offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddys major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.

Read also: Dr Reddy's Laboratories gets CDSCO Panel Nod To Import and Market Toripalimab 240mg solution for infusion

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News